Ross Maltz - Biosimilars, Advocacy, and More IBD Medication Updates
Mon Jan 26 2026
In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jenn Lee talk to Dr. Ross Maltz, pediatric gastroenterologist at Nationwide Children's Hospital and Associate Professor at The Ohio State University College of Medicine. He is Director of the Very Early Onset Inflammatory Bowel Disease (VEOIBD) Program and Research Director of the Inflammatory Bowel Disease Center at Nationwide Children's.
He provides a massive update on all things IBD medications, including discussing the latest on biosimilar medications, the medications we have available and their positioning, and new things in the pipeline.
Dr. Maltz does not have any conflicts of interest to disclose.
Learning objectives
Understand the safety and efficacy of biosimilar medications for children with IBD.Review the latest guidance on medications available for treatment of children with IBD.Discuss opportunities for advocacy to provide better access to IBD medications for children.Support the show
This episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!
As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.
Check out our merch website!
Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.
Click here to support the show.
More
In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jenn Lee talk to Dr. Ross Maltz, pediatric gastroenterologist at Nationwide Children's Hospital and Associate Professor at The Ohio State University College of Medicine. He is Director of the Very Early Onset Inflammatory Bowel Disease (VEOIBD) Program and Research Director of the Inflammatory Bowel Disease Center at Nationwide Children's. He provides a massive update on all things IBD medications, including discussing the latest on biosimilar medications, the medications we have available and their positioning, and new things in the pipeline. Dr. Maltz does not have any conflicts of interest to disclose. Learning objectives Understand the safety and efficacy of biosimilar medications for children with IBD.Review the latest guidance on medications available for treatment of children with IBD.Discuss opportunities for advocacy to provide better access to IBD medications for children.Support the show This episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review! As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field. Check out our merch website! Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes. Click here to support the show.